The DOI matches its Crossref record; 177 of the 178 references it cites were found in a registry or an index.
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer
Abstract
Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific type of breast cancer for more than 30 years. Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) have been demonstrated to be effective therapeutic approaches for ER positive breast cancers. Unfortunately, 30-50% of ER positive tumors become resistant to SERM/AI treatment after 3-5 years. Fulvestrant, the only approved selective estrogen receptor degrader (SERD), is currently an important therapeutic approach for the treatment of endocrine-resistant breast cancers. The poor pharmacokinetic properties of fulvestrant have inspired the development of a new generation of oral SERDs to overcome drug resistance. In this review, we describe recent advances in ERα structure, functions, and mechanisms of endocrine resistance and summarize the development of oral SERDs in both academic and industrial areas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fulvestrant is a standard therapeutic option for endocrine-resistant or advanced metastatic ER+ breast cancer59,60.”
From Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha (2025) · cites this paper as [60]
Citations
Cites
1 retracted
Wong, C., McNally, C., Nickbarg, E., Komm, B. S., & Cheskis, B. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192569699 · Cited by 321
RetractedMolecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Self-citationPhenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O. A., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,290
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Nuclear Receptor Coregulators: Cellular and Molecular Biology
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,941
† (2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,550
Research works printed but not linked: 8
- Ottaviano Y. L., 1994, Cancer Res., 54, 2552
- Lapidus R. G., 1996, Clin. Cancer Res., 2, 805
- Yang X., 2001, Cancer Res., 61, 7025
- Zhang Q.-X., 1997, Cancer Res., 57, 1244
- Wakeling A. E., 1991, Cancer Res., 51, 3867
- Wakeling A., 1980, Cancer Treat. Rep., 64, 741
- Pink J. J., 1996, Cancer Res., 56, 2321
- Müller V., 1998, Cancer Res., 58, 263
Cited by
Sorted by citations
Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
Burke, M. R., Smith, A. R., & Zheng, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.872729 · Cited by 129
Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
Rej, R. K., Thomas, J. E., Acharyya, R. K., Rae, J. M., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00136 · Cited by 117
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
Accelerating drug development in breast cancer: New frontiers for ER inhibition
Ferraro, E., Walsh, E. M., Tao, J. J., Chandarlapaty, S., & Jhaveri, K. L. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102432 · Cited by 57
Chen, Z., Hu, B., Rej, R. K., Wu, D., Acharyya, R. K., Wang, M., Xu, T., Lü, J., Metwally, H., Wang, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01186 · Cited by 54
Metadata
- Authors
- Lu, Y., & Liu, W.
- Affiliations
- Nanjing University of Chinese Medicine (CN)
- Corresponding author
- Lu, Yunlong
- Liu, Wukun
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-11-02
- Volume
- 63
- Issue
- 24
- Pages
- 15094-15114
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3094721087
- Cited by
- 119
- References
- 178
- Citations by year
- 2026: 20 · 2025: 22 · 2024: 29 · 2023: 29 · 2022: 12 · 2021: 7
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Jiangsu Provincial Department of Education
- State Key Laboratory of Natural Medicines (SKLNMKF201712, SKLNMKF201808)
- Six Talent Peaks Project in Jiangsu Province (SWYY-069)
- National Natural Science Foundation of China (81703337)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- State Key Laboratory of Coordination Chemistry, Nanjing University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- selective estrogen receptor degrader, estrogen receptor-positive breast cancer, endocrine therapy resistance, fulvestrant, aromatase inhibitors, selective estrogen receptor modulators, drug resistance mechanisms
- MeSH terms
- Fulvestrant, Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Steroids, Structure-Activity Relationship, Signal Transduction, Drug Resistance, Neoplasm, Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Estrogen Receptor alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
